Shlomit Yust-Katz

OncoDaily

News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary

Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me

May, 2025

Shlomit Yust-Katz

Oct 31, 2024, 12:37 | Blog

Vorasidenib doubled PFS for patients with Grade 2 gliomas with IDH1 or IDH2 mutations - Dana-Farber Cancer Institute

Dana-Farber Cancer Institute shared on LinkedIn: "In a global phase 3, double-blinded, randomized clinical trial,…

Oct 26, 2024, 10:21 | Drugs

Health Canada Approves First and Only Oral Targeted Treatment for Brain Cancer

LAVAL, QC, Oct. 22, 2024 /CNW/ – Servier Canada is pleased to announce the approval and commercial availability…

Sep 13, 2024, 13:59 | Insight

Article of the day, September 13th, suggested by the Immune Oncology Research Institute

Immune Oncology Research Institute shared a post on LinkedIn: “Article of the day! Suggest by the Immune…

All: 3 Posts: 1 - 100

'

Francesco Acerbi and Testicular Cancer: The Defender's Fight and Triumphant Return to Football

'

Yvonne Award for Breakthrough Research 2024 Recipient to Time100 Health List

'

Dr Saunthari Somasundaram is the new President-Elect of the NCD Alliance

'

Does Plastic Cause Cancer? Myths and Facts

'

TOPGEAR trial at ESTRO 2025: Preoperative Chemoradiotherapy for Resectable Gastric Cancer

Special Coverage

Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
ESMO 2024 Congress
September 13-17, 2024
ASCO Annual Meeting
May 30 - June 4, 2024
Yvonne Award 2024
May 31, 2024
OncoThon 2024, Online
Feb. 15, 2024
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023